As listed companies recently disclosed their 2025 annual financial reports, a comprehensive review of operational data from 24 chemical pharmaceutical firms has been conducted. By analyzing full-dimensional operational data from 2024 to 2025 for companies such as InnoCare Pharma, Hengrui Pharmaceuticals, and Livzon Pharmaceutical Group, this report examines the industry landscape across five key dimensions: company scale, R&D investment, profitability, operational efficiency, and talent incentives. The analysis identifies top and bottom performers across various metrics, providing data-driven insights for industry development and investment decisions.
Company scale shows significant disparity among leading firms, with Fosun Pharma and Hengrui Pharmaceuticals emerging as the dominant players in terms of size. Total employee count, a key indicator of production capacity, market coverage, and supply chain layout, reveals a pattern of concentration among top players and notable gaps across specialized segments. The scale structure remained largely stable from 2024 to 2025, with only minor workforce adjustments in some companies.
In 2025, the largest companies by employee count were all in the chemical formulation sector. Fosun Pharma led with 40,603 employees, up 1.83% from 39,872 in 2024, making it the only firm in the industry with over 40,000 employees, supported by its global presence and integrated supply chain advantages. Hengrui Pharmaceuticals followed with 20,602 employees, a 1.80% increase from 20,238 in 2024, maintaining leadership in both scale and innovation as a top innovative drug developer. Huaren Shuanghe ranked third with 13,184 employees, up 2.40% from 12,876 in 2024, sustaining its scale advantage in the generic drug segment. These three companies each employed over 10,000 people, collectively accounting for 42.3% of the total workforce among the 24 firms, highlighting their significant scale advantage.
Smaller companies primarily exhibited innovative and compact characteristics. For instance, MicuRx Pharmaceuticals-U and Huangshan Capsule Haisun Pharmaceutical each had fewer than 800 employees. MicuRx Pharmaceuticals-U, as an innovative drugmaker, had the smallest workforce at just 166 employees, reflecting its strong R&D focus but limited commercial maturity. Huangshan Capsule and Haisun Pharmaceutical, focused on active pharmaceutical ingredient (API) production, required smaller teams due to the standardized nature of their operations, with 639 and 705 employees, respectively.
Across segments, the average employee count for chemical formulation companies was 7,404, 2.62 times that of API manufacturers, underscoring the scale advantage of formulation firms. This disparity stems from the broader business scope of formulation companies, which cover the entire value chain from R&D and production to sales, compared to the production-focused operations of API firms.
R&D investment is a core measure of innovation capability in the chemical pharmaceutical industry, directly influencing competitiveness in patented drugs, high-end generics, and specialty APIs. In 2025, R&D spending showed a clear divergence, with formulation companies far outstripping API producers and innovative drugmakers breaking from conventional patterns.
Top R&D spenders were all innovative formulation companies. MicuRx Pharmaceuticals-U led with an R&D expense ratio of 151.00%, followed by Mabwell Biotechnology-U at 147.46%, and Zai Lab-U at 53.04%. Additionally, InnoCare Pharma and Hengrui Pharmaceuticals both reported R&D expense ratios exceeding 20%.
In contrast, the lowest R&D spenders were concentrated in the API sector. Huangshan Capsule had an R&D expense ratio of 2.75%, Guobang Pharmaceutical 3.49%, and Xinhua Pharmaceutical 4.36%, all below 5%. API manufacturers typically focus R&D on process improvements rather than new drug development, resulting in lower product value-added and weaker bargaining power within the supply chain.
On average, chemical formulation companies had an R&D expense ratio of 33.00%, 2.54 times that of API firms. Within the formulation segment, a significant gap also existed between innovative and traditional generic drugmakers, indicating a concentration of innovation resources in high-value areas.
Gross profit margin serves as a key indicator of product competitiveness, pricing power, and profit potential, reflecting the market value of core products. The ratio of net cash flow from operating activities to revenue measures profit quality and the ability to convert book profits into cash. Combined, these metrics provide a comprehensive assessment of profitability. In 2025, the industry exhibited a pronounced lead by chemical formulation companies, while API manufacturers faced constrained profit margins.
Top performers in gross margin were all innovative formulation companies. InnoCare Pharma achieved a gross margin of 91.95%, Zai Lab-U 90.42%, and Mabwell Biotechnology-U 90.27%, approaching levels seen in luxury goods sectors. High margins are driven by patent protection and strong pricing power for innovative drugs, enabling significant profit potential despite substantial R&D costs. Established players like Hengrui Pharmaceuticals and Deyuan Pharmaceutical also demonstrated strong profitability with gross margins of 86.21% and 84.08%, respectively.
The lowest gross margins were found among API producers. Xinhua Pharmaceutical had a gross margin of 18.78%, Guobang Pharmaceutical 26.03%, and Apeloa Pharmaceutical 26.36%, all below 30%. These companies face pressures from raw material price volatility and intense competition, relying on economies of scale to maintain profits, which severely limits their margin potential. The gap between the highest and lowest gross margins reached 4.9 times, highlighting stark profitability divergence across the industry.
In terms of cash flow, Hengrui Pharmaceuticals, Haisun Pharmaceutical, and Livzon Pharmaceutical Group achieved cash flow-to-revenue ratios exceeding 25%, indicating high profit quality. Hengrui Pharmaceuticals effectively converted high gross margins into cash through robust sales channels and accounts receivable management. Despite lower margins, Haisun Pharmaceutical delivered superior cash flow performance compared to some formulation companies via efficient operations.
The weakest cash flow performers were primarily innovative formulation companies. Mabwell Biotechnology-U had a cash flow-to-revenue ratio of -43.81%, Zai Lab-U -3.55%, and InnoCare Pharma 3.53%, with Mabwell reporting a negative figure. These firms experience cash flow strain due to high R&D expenditures and incomplete commercialization, often relying on external financing to sustain operations.
Operating cycle, a core metric of operational efficiency, measures the time required from inventory acquisition to sales and cash collection. Shorter cycles indicate faster inventory turnover and accounts receivable collection, leading to higher capital efficiency. Longer cycles suggest excessive capital tied up in operations.
API manufacturers, with standardized products and shorter sales cycles, excel in inventory and receivables management, enabling quicker cash recovery. Top performers in operational efficiency were all API companies. Xinhua Pharmaceutical had an operating cycle of 101.20 days, Xintiandi 123.41 days, and Apeloa Pharmaceutical 150.48 days, demonstrating high efficiency.
In contrast, the least efficient operators were mainly innovative formulation companies. Mabwell Biotechnology-U reported an operating cycle of 1,153.12 days, MicuRx Pharmaceuticals-U 951.35 days, and Zai Lab-U 891.10 days. Extended cycles result from lengthy drug development timelines, slow commercialization, and reliance on healthcare institution clients, which leads to prolonged receivables collection and significant capital occupation.
On average, the operating cycle for API firms was 51.1% of that for chemical formulation companies. Within the formulation segment, a notable efficiency gap also existed between innovative and generic drugmakers, reflecting the direct link between operational efficiency and business models.
Average salary per employee is a key measure of talent attraction, incentive levels, and corporate soft power, crucial for securing and retaining skilled R&D, production, and sales personnel. In 2025, the industry displayed a pattern of high compensation in innovative formulation firms and lower remuneration in API companies, with most firms increasing salaries from 2024 to 2025.
Top payers were all innovative formulation companies. MicuRx Pharmaceuticals-U led with an average salary of 582,700 yuan per employee, followed by InnoCare Pharma at 539,600 yuan, and Zai Lab-U at 386,700 yuan, all significantly above the industry average. Attracting top R&D talent necessitates high compensation, supported by external funding. Hengrui Pharmaceuticals, as an established leader, also ranked highly with an average salary of 343,100 yuan, demonstrating strong competitiveness in talent retention.
The lowest payers were concentrated in the API sector. Tuoxin Pharmaceutical had an average salary of 88,900 yuan per employee, Xintiandi 96,800 yuan, and Haisun Pharmaceutical 121,500 yuan. With a workforce primarily engaged in production roles requiring lower specialized skills and limited profitability, API firms struggle to support high salary levels. On average, chemical formulation companies paid 2.02 times the average salary of API manufacturers, indicating a significant gap in talent attraction.